Parkinson’s disease.
Parkinson’s disease is a progressive neurodegenerative disorder that affects more than 12 million people worldwide
Current available treatments do not halt the progression of the disease.
Our approach is targeting this gap and changing the course of the disease. Parkinson’s disease is not just a movement disorder; it is a complex, multi-system disease that requires a fundamentally new approach.
Parkinson’s disease causes debilitating motor symptoms such as tremors, rigidity, and slowed movement, and is consistently accompanied by a wide range of non-motor complications, including cognitive decline, mood disorders, sleep disturbances, and reduced sense of smell. The disease is characterized by the loss of nerve cells in the brain that produce a neurotransmitter, called dopamine. This loss of so-called dopaminergic neurons occurs in brain regions crucial for movement control. This degradation is leading to a variety of symptoms.
Parkinson’s disease is slowly progressing, which means that there is more neurodegeneration over time and symptoms get worse. Current treatment options can help patients to cope with these symptoms for a period of time while the disease progresses.
One of the contributing factors to the progression is the aggregation of a protein called alpha-synuclein. This protein damages the neurons and finally leads to cellular death and brain degeneration. Factors like oxidative stress and dysfunction of cellular mechanisms including mitochondrial impairment play a key role and drive the disease progression.
Despite decades of research, today’s standard treatments only temporarily manage symptoms, but none of the available drugs is capable altering the underlying course of the disease. There is a critical and urgent need for therapies that goes beyond symptom relief.
At Teitur, we are working toward a novel unique and innovative approach to slow down or halt the disease progression.
.jpg)
Ressources.
Parkinson’s Europe – Understanding Parkinson’s
The Michael J. Fox Foundation – Parkinson’s 101
We’re excited to share our latest updates, milestones, and breakthroughs with you.
Find all our press releases, news articles, and announcements here — straight from Teitur Trophics.
Recent news
Teitur Hosts First Scientific Advisory Board Meeting for Lead Program TT-P34
Teitur Trophics has recently hosted its first Scientific Advisory Board (SAB) Meeting. This is an important milestone in the development of Teitur's lead program, TT-P34. We brought together a distinguished panel of internationally recognized Parkinson’s disease and translational medicine experts:
Dr. Günter Höglinger (LMU Munich)
Dr. Margherita Fabbri (CHU Toulouse)
Dr. Nicola Pavese (NIHR Newcastle)
Dr. Joachim Scholpp (Industry Executive & Advisor)
During the meeting, our advisors shared invaluable insights, experience, and strategic guidance to help shape the next steps in TT-P34’s development. The discussion focused on refining the Phase II planning and strategy for TT-P34, a novel peptide-based therapeutic targeting mitochondrial and lysosomal dysfunction. Their contributions are critical to our efforts to optimize our development strategy and move this promising therapy closer to the first patient trial.
This first SAB marks an important step forward in Teitur’s mission to develop transformative treatments for neurodegenerative diseases.
Teitur Trophics receives Eurostars funding to support pipeline project in hearing loss
We are thrilled to announce that Teitur has received a Eurostars grant for the project Breakthrough Regenerative Peptide Therapy to Cure Patients with Sensorineural Hearing Loss (RE-HEAR). The RE-HEAR project is a collaboration between Teitur Trophics, the French biotech company CILcare and the School of Life Sciences at the University of Applied Sciences Northwestern Switzerland (FHNW) and aims to advance novel peptide-based therapeutics targeting hidden hearing loss and age-related hearing loss.
Teitur’s proprietary peptides harness a unique targeted action on pathways of the SorCS2 receptor, potentially providing sustained therapeutic effects, beneficial to patients with sensorineural hearing loss. The €2M RE-HEAR project aims to progress peptides through preclinical proof of concept studies. This initiative encompasses research on delivery methods, as well as in vivo and in vitro efficacy evaluations using innovative hearing loss models created by CILcare and FHNW specifically for this project.
Re-HEAR will run over a 36-month period and is set to commence in April 2025. A huge thank you to Eurostars and Innovationsfonden for believing in our vision and supporting our mission. Stay tuned for more updates as we continue our journey towards making a meaningful impact in the hearing loss space!
Sejelas Founder-CEO Interview with Simon Mølgaard
Our CEO Simon Mølgaard was interviewed by Sejelas where he talks about Teitur Trophics and our commitment to developing novel treatments for treating patients suffering from neurodegenerative diseases.
Teitur Trophics receives grant from Innobooster to support biomarker development
We are thrilled and honored to announce that Teitur has received a grant from Innobooster to support our groundbreaking work on identifying novel biomarkers for treating Huntington's Disease (HD).
This funding will propel our research forward, bringing us closer to innovative solutions that can significantly improve the lives of those affected by HD. A huge thank you to Innobooster for believing in our vision and supporting our mission.
Stay tuned for more updates as we continue our journey towards making a meaningful impact in the field of neurodegenerative diseases!
Teitur Trophics ApS become part of Incuba Skejby
We are very happy to become a part of the great innovative environment at Incuba Skejby, where we are able to develop and grow in our new offices and laboratories.
Teitur Trophics has been nominated for EY Entrepreneur of The Year - Life Sciences
The team at Teitur are extremely honoured to have been nominated for EY Entrepreneur of The Year - Life Sciences. The nomination recognizes the development the company has gone through since starting in 2020. The Award Ceremony will take place on 23th November at Lokomotivværkstedet in Copenhagen.
Teitur Trophics has been nominated for European Lifestars Award - Series A: Finance raise of the year
We are excited to be nominated for European Lifestars Award – Series A: Finance raise of the year. The nomination is a testament to the incredible team at Teitur Trophics and our ambition and commitment is to create new treatments for patients suffering from neurodegenerative diseases. The Award Ceremony will take place on 13th November at the Honourable Artillery Company venue in London, during the 2023 European Lifestars Awards Reception.
Teitur Trophics Raises EUR 28M in Series A Financing to Advance the Development and Treatment for Neurodegenerative Diseases
Teitur today announces the completion of a €28M Series A financing. The financing was co-led by Sunstone Life Science Ventures and Sound Bioventures, with participation from new investors, Industrifonden, Innovestor’s Life Science Fund and P53 Invest. The proceeds will enable Teitur to progress its lead drug candidate, TT-P34, from candidate selection into clinical development, including a Phase 1b clinical study in neurodegenerative diseases.
Teitur, a spin out from Aarhus University seeded by the BioInnovation Institute (“BII”) in 2020, has developed a platform of first-in-class cyclic peptides with a novel mechanism that preserves neuronal function. The peptides have the potential to treat patients suffering from a broad range of neurodegenerative diseases. Lead drug candidate, TT-P34, is administered subcutaneously and has shown potent, brain specific effects in animal models for Huntington’s Disease, Parkinson’s Disease and Frontotemporal Dementia.
TT-P34 was developed from the sortilin-related Vps10p domain containing receptor (“SorCS2”) receptor and acts by targeting the three major pathophysiological hallmarks of neurodegeneration: mitochondrial failure, lysosomal dysfunction, and loss of pro-survival signaling. TT-P34 uniquely restores energy homeostasis in brain cells, induces clearance of toxic protein aggregates and promotes neurotrophic effects, thereby supporting neuronal cell survival in neurodegenerative diseases.
Simon Mølgaard, Chief Executive Officer of Teitur Trophics said: “We are very pleased to welcome Sound Bioventures, Industrifonden, Innovestor’s Life Science Fund and P53 Invest to Teitur, who will join our existing investor Sunstone Life Science Ventures. This investor syndicate creates a very strong and committed shareholder base with a track record of supporting successful next generation companies. The €28 million Series A investment further validates our vision for preserving neuronal function in the face of these devastating neurodegenerative disorders. The funding will allow us to take our first-in-class, lead drug candidate, TT-P34 from candidate selection into clinical development, while also advancing our novel pipeline of innovative peptides. There is a pressing need for new therapies for neurodegenerative diseases which have a detrimental impact on millions of people’s lives around the world, with serious implications for quality of life and life expectancy.”
Søren Lemonius, General Partner at Sunstone Life Science Ventures, commented: “We are delighted to further support Teitur at this pivotal time of Company growth and development. Our passion is to enable and empower therapeutic innovation that has the ability to improve patient outcomes and we believe Teitur’s cyclic peptides is yet another excellent example of the breakthrough science coming out of the Scandinavian biotech ecosystem.”
Casper Breum, Managing Partner at Sound Bioventures added: "We are proud to support such an innovative Company that has the potential to make a meaningful impact against neurodegenerative diseases and improve the quality of life of patients, and we look forward to supporting the Company through its next stage of growth.”
In conjunction with the Series A financing, Charles Large will continue as Chairman of the Board at Teitur, while Søren Lemonius, Casper Breum, Fredrik Lehmann, Milla Koistinaho and Susanne Stuffers will join the Teitur Board of Directors.
-ENDS-
For further information, please contact:
Optimum Strategic Communications
Hollie Vile, Richard Staines, Zoe Bolt
Tel: +44 (0) 20 3882 9621
Email: teitur@optimumcomms.com
About Teitur Trophics
Teitur Trophics, founded by Simon Molgaard, Anders Dalby, Mathias Ollendorff and Simon Glerup, is a biotech company that targets neurodegenerative diseases, based in Aarhus, Denmark. It is developing first-in-class circular peptides for treating neurodegenerative disorders, where there are no treatments currently available including Parkinson’s Disease, Frontotemporal Dementia and Huntington's Disease. Its lead drug candidate, TT-P34, works by clearing the toxic protein deposits implicated in neurodegenerative diseases, restoring the function of mitochondria in affected brain cells and promoting pro-survival signaling. For more information, please visit: www.TeiturTrophics.com
About Sunstone Life Science Ventures
Sunstone Life Science Ventures is an independent European venture capital investment firm founded in 2007 by an international team of industry experts with combined entrepreneurial, operational and financial experience. Managing total funds of €500 million, Sunstone Life Science Ventures focuses on developing and expanding early‐stage Life Science companies with strong potential to achieve global success in their markets. Since the inception, Sunstone Life Science Ventures has invested in more than 50 companies in the areas of pharmaceuticals, medical technologies and diagnostics, and has completed more than 20 successful IPOs and large M&A transactions. For more information, please visit: https://sunstone.eu/
About Sound Bioventures
Sound Bioventures is a biotherapeutics focused venture fund, that invests in about-to-be clinical or clinical stage companies in Europe and USA, and with a strong foundation in the Nordic biotech ecosystem. Founded by a team of experienced life science investors and operators, the fund invests in projects addressing significant unmet medical needs having the potential for a profound impact on human health and healthcare systems. For more information, please visit: www.soundbioventures.com
About Industrifonden
Industrifonden is Sweden’s Venture Capital Fund looking for unique, scalable innovation that has a meaningful impact on our society. Industrifonden manages more than SEK 5 billion and invest in early-stage companies, from seed to A-round funding with a reach across the Nordics. The investment focus includes specialized technologies and businesses within Deep Tech, Life Science and Transformative Tech. Industrifonden has an evergreen structure which allows a long-term focus on value creation. Read more at www.industrifonden.com
About Innovestor
Innovestor is a Finnish investment company focusing on venture capital and real estate. In addition, we offer corporate venturing services. The firm currently manages four VC funds with total capital of over €200 million. Consisting of almost 100 growth companies across multiple sectors of technology and life science & health, it represents one of the largest private venture-backed portfolios in the Nordics. Our mission is to make good money. For more information, visit www.innovestorgroup.com
About P53 Invest
P53 Invest is a Norwegian investment company that identifies and invests in healthcare companies that think new and disrupt the status quo. P53 seeks to contribute to the development and commercialization of ground-breaking ideas that transform people’s lives, increase accessibility to cutting-edge treatments and innovative healthcare solutions and create exceptional value for patients. For more information, please visit: www.p53.no
Teitur Trophics receives Innobooster grant to develop candidate towards IND
Teitur is happy to have secured funding from the Innobooster grant from Innovation Fund Denmark. The grant will allow the company to finalize studies to nominate a candidate for IND enabling studies
Teitur Trophics closes convertible loan from Sunstone Life Science Ventures
Teitur today announces the successful closing of a €400.000 convertible loan from Sunstone to advance the preclinical program targeting neurodegenerative diseases.
Teitur receives Innobooster grant from Innovation Fund Denmark for advancing HD program
Teitur is happy to have secured funding from the Innobooster grant from Innovation Fund Denmark. The grant will enable the company to advance the innovative peptide project for treating patients suffering from Huntington’s Disease.
.jpg)
Teitur Trophics joins the BII Creation House program
The biotech company Teitur Trophics that targets neurodegenerative diseases has joined the BII Creation House program. As part of the Creation House program, Teitur Trophics will have access to a global network of life science entrepreneurs and investors, labs and office space, business development and DKK 10M in funding during the coming 18 months.
August 22, 2025
Teitur Hosts First Scientific Advisory Board Meeting for Lead Program TT-P34
Teitur Trophics has recently hosted its first Scientific Advisory Board (SAB) Meeting. This is an important milestone in the development of Teitur's lead program, TT-P34. We brought together a distinguished panel of internationally recognized Parkinson’s disease and translational medicine experts:
Dr. Günter Höglinger (LMU Munich)
Dr. Margherita Fabbri (CHU Toulouse)
Dr. Nicola Pavese (NIHR Newcastle)
Dr. Joachim Scholpp (Industry Executive & Advisor)
During the meeting, our advisors shared invaluable insights, experience, and strategic guidance to help shape the next steps in TT-P34’s development. The discussion focused on refining the Phase II planning and strategy for TT-P34, a novel peptide-based therapeutic targeting mitochondrial and lysosomal dysfunction. Their contributions are critical to our efforts to optimize our development strategy and move this promising therapy closer to the first patient trial.
This first SAB marks an important step forward in Teitur’s mission to develop transformative treatments for neurodegenerative diseases.
X
February 5, 2025
Teitur Trophics receives Eurostars funding to support pipeline project in hearing loss
We are thrilled to announce that Teitur has received a Eurostars grant for the project Breakthrough Regenerative Peptide Therapy to Cure Patients with Sensorineural Hearing Loss (RE-HEAR). The RE-HEAR project is a collaboration between Teitur Trophics, the French biotech company CILcare and the School of Life Sciences at the University of Applied Sciences Northwestern Switzerland (FHNW) and aims to advance novel peptide-based therapeutics targeting hidden hearing loss and age-related hearing loss.
Teitur’s proprietary peptides harness a unique targeted action on pathways of the SorCS2 receptor, potentially providing sustained therapeutic effects, beneficial to patients with sensorineural hearing loss. The €2M RE-HEAR project aims to progress peptides through preclinical proof of concept studies. This initiative encompasses research on delivery methods, as well as in vivo and in vitro efficacy evaluations using innovative hearing loss models created by CILcare and FHNW specifically for this project.
Re-HEAR will run over a 36-month period and is set to commence in April 2025. A huge thank you to Eurostars and Innovationsfonden for believing in our vision and supporting our mission. Stay tuned for more updates as we continue our journey towards making a meaningful impact in the hearing loss space!
X
July 9, 2024
Teitur Trophics receives grant from Innobooster to support biomarker development
We are thrilled and honored to announce that Teitur has received a grant from Innobooster to support our groundbreaking work on identifying novel biomarkers for treating Huntington's Disease (HD).
This funding will propel our research forward, bringing us closer to innovative solutions that can significantly improve the lives of those affected by HD. A huge thank you to Innobooster for believing in our vision and supporting our mission.
Stay tuned for more updates as we continue our journey towards making a meaningful impact in the field of neurodegenerative diseases!
X
October 31, 2023
Teitur Trophics has been nominated for EY Entrepreneur of The Year - Life Sciences
The team at Teitur are extremely honoured to have been nominated for EY Entrepreneur of The Year - Life Sciences. The nomination recognizes the development the company has gone through since starting in 2020. The Award Ceremony will take place on 23th November at Lokomotivværkstedet in Copenhagen.
X
October 6, 2023
Teitur Trophics has been nominated for European Lifestars Award - Series A: Finance raise of the year
We are excited to be nominated for European Lifestars Award – Series A: Finance raise of the year. The nomination is a testament to the incredible team at Teitur Trophics and our ambition and commitment is to create new treatments for patients suffering from neurodegenerative diseases. The Award Ceremony will take place on 13th November at the Honourable Artillery Company venue in London, during the 2023 European Lifestars Awards Reception.
X
March 14, 2023
Teitur Trophics Raises EUR 28M in Series A Financing to Advance the Development and Treatment for Neurodegenerative Diseases
Teitur today announces the completion of a €28M Series A financing. The financing was co-led by Sunstone Life Science Ventures and Sound Bioventures, with participation from new investors, Industrifonden, Innovestor’s Life Science Fund and P53 Invest. The proceeds will enable Teitur to progress its lead drug candidate, TT-P34, from candidate selection into clinical development, including a Phase 1b clinical study in neurodegenerative diseases.
Teitur, a spin out from Aarhus University seeded by the BioInnovation Institute (“BII”) in 2020, has developed a platform of first-in-class cyclic peptides with a novel mechanism that preserves neuronal function. The peptides have the potential to treat patients suffering from a broad range of neurodegenerative diseases. Lead drug candidate, TT-P34, is administered subcutaneously and has shown potent, brain specific effects in animal models for Huntington’s Disease, Parkinson’s Disease and Frontotemporal Dementia.
TT-P34 was developed from the sortilin-related Vps10p domain containing receptor (“SorCS2”) receptor and acts by targeting the three major pathophysiological hallmarks of neurodegeneration: mitochondrial failure, lysosomal dysfunction, and loss of pro-survival signaling. TT-P34 uniquely restores energy homeostasis in brain cells, induces clearance of toxic protein aggregates and promotes neurotrophic effects, thereby supporting neuronal cell survival in neurodegenerative diseases.
Simon Mølgaard, Chief Executive Officer of Teitur Trophics said: “We are very pleased to welcome Sound Bioventures, Industrifonden, Innovestor’s Life Science Fund and P53 Invest to Teitur, who will join our existing investor Sunstone Life Science Ventures. This investor syndicate creates a very strong and committed shareholder base with a track record of supporting successful next generation companies. The €28 million Series A investment further validates our vision for preserving neuronal function in the face of these devastating neurodegenerative disorders. The funding will allow us to take our first-in-class, lead drug candidate, TT-P34 from candidate selection into clinical development, while also advancing our novel pipeline of innovative peptides. There is a pressing need for new therapies for neurodegenerative diseases which have a detrimental impact on millions of people’s lives around the world, with serious implications for quality of life and life expectancy.”
Søren Lemonius, General Partner at Sunstone Life Science Ventures, commented: “We are delighted to further support Teitur at this pivotal time of Company growth and development. Our passion is to enable and empower therapeutic innovation that has the ability to improve patient outcomes and we believe Teitur’s cyclic peptides is yet another excellent example of the breakthrough science coming out of the Scandinavian biotech ecosystem.”
Casper Breum, Managing Partner at Sound Bioventures added: "We are proud to support such an innovative Company that has the potential to make a meaningful impact against neurodegenerative diseases and improve the quality of life of patients, and we look forward to supporting the Company through its next stage of growth.”
In conjunction with the Series A financing, Charles Large will continue as Chairman of the Board at Teitur, while Søren Lemonius, Casper Breum, Fredrik Lehmann, Milla Koistinaho and Susanne Stuffers will join the Teitur Board of Directors.
-ENDS-
For further information, please contact:
Optimum Strategic Communications
Hollie Vile, Richard Staines, Zoe Bolt
Tel: +44 (0) 20 3882 9621
Email: teitur@optimumcomms.com
About Teitur Trophics
Teitur Trophics, founded by Simon Molgaard, Anders Dalby, Mathias Ollendorff and Simon Glerup, is a biotech company that targets neurodegenerative diseases, based in Aarhus, Denmark. It is developing first-in-class circular peptides for treating neurodegenerative disorders, where there are no treatments currently available including Parkinson’s Disease, Frontotemporal Dementia and Huntington's Disease. Its lead drug candidate, TT-P34, works by clearing the toxic protein deposits implicated in neurodegenerative diseases, restoring the function of mitochondria in affected brain cells and promoting pro-survival signaling. For more information, please visit: www.TeiturTrophics.com
About Sunstone Life Science Ventures
Sunstone Life Science Ventures is an independent European venture capital investment firm founded in 2007 by an international team of industry experts with combined entrepreneurial, operational and financial experience. Managing total funds of €500 million, Sunstone Life Science Ventures focuses on developing and expanding early‐stage Life Science companies with strong potential to achieve global success in their markets. Since the inception, Sunstone Life Science Ventures has invested in more than 50 companies in the areas of pharmaceuticals, medical technologies and diagnostics, and has completed more than 20 successful IPOs and large M&A transactions. For more information, please visit: https://sunstone.eu/
About Sound Bioventures
Sound Bioventures is a biotherapeutics focused venture fund, that invests in about-to-be clinical or clinical stage companies in Europe and USA, and with a strong foundation in the Nordic biotech ecosystem. Founded by a team of experienced life science investors and operators, the fund invests in projects addressing significant unmet medical needs having the potential for a profound impact on human health and healthcare systems. For more information, please visit: www.soundbioventures.com
About Industrifonden
Industrifonden is Sweden’s Venture Capital Fund looking for unique, scalable innovation that has a meaningful impact on our society. Industrifonden manages more than SEK 5 billion and invest in early-stage companies, from seed to A-round funding with a reach across the Nordics. The investment focus includes specialized technologies and businesses within Deep Tech, Life Science and Transformative Tech. Industrifonden has an evergreen structure which allows a long-term focus on value creation. Read more at www.industrifonden.com
About Innovestor
Innovestor is a Finnish investment company focusing on venture capital and real estate. In addition, we offer corporate venturing services. The firm currently manages four VC funds with total capital of over €200 million. Consisting of almost 100 growth companies across multiple sectors of technology and life science & health, it represents one of the largest private venture-backed portfolios in the Nordics. Our mission is to make good money. For more information, visit www.innovestorgroup.com
About P53 Invest
P53 Invest is a Norwegian investment company that identifies and invests in healthcare companies that think new and disrupt the status quo. P53 seeks to contribute to the development and commercialization of ground-breaking ideas that transform people’s lives, increase accessibility to cutting-edge treatments and innovative healthcare solutions and create exceptional value for patients. For more information, please visit: www.p53.no
X
October 15, 2020
Teitur receives Innobooster grant from Innovation Fund Denmark for advancing HD program
Teitur is happy to have secured funding from the Innobooster grant from Innovation Fund Denmark. The grant will enable the company to advance the innovative peptide project for treating patients suffering from Huntington’s Disease.
X
March 31, 2020
Teitur Trophics joins the BII Creation House program
The biotech company Teitur Trophics that targets neurodegenerative diseases has joined the BII Creation House program. As part of the Creation House program, Teitur Trophics will have access to a global network of life science entrepreneurs and investors, labs and office space, business development and DKK 10M in funding during the coming 18 months.
X